The role of Noradrenaline, Acetylcholine and NMDA in conscious perception

The role of Noradrenaline, Acetylcholine and NMDA in conscious perception - NA, ACh, NMDA, and conscious perception

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON48993

Enrollment

210

Registered

2018-07-23

Start date

2019-05-24

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geen aandoening, dit onderzoek richt zich op de werking van het gezonde brein. Not applicable

Interventions

Participants will receive 40mg atomoxetine, 5mg donepezil, 20mg memantine or placebo on four different test sessions, in a randomized order.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers between 18 and 30 years old; Native Dutch speakers; Predominant right-handedness; BMI between 18.5 and 30. Male

Exclusion criteria

Exclusion criteria: Current or history of any medical or psychiatric disorder or disease Smoking Allergy for atomoxetine, donepezil, memantine or one of the inactive ingredients of these products

Design outcomes

Primary

Measure	Time frame
Primary study parameters include behavioral reaction times and performance scores and EEG-, MEG- and fMRI-measures.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)